Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

2651 - NACC1 as a target of microRNA-331-3p regulates cell proliferation in urothelial carcinoma cells

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Kohei Morita

Citation

Annals of Oncology (2018) 29 (suppl_8): viii670-viii682. 10.1093/annonc/mdy304

Authors

K. Morita1, T. Fujii2, K. Shimada3, H. Itami1, K. Hatakeyama1, M. Miyake4, K. Fujimoto4, C. Ohbayashi1

Author affiliations

  • 1 Diagnostic Pathology, Nara Medical University, 634-8521 - Nara/JP
  • 2 Clinical Pathology, Nara Medical University, Nara/JP
  • 3 Diagnostic Pathology, Nara City Hospital, 630-8305 - Nara/JP
  • 4 Urology, Nara Medical University, 634-8521 - Nara/JP
More

Resources

Abstract 2651

Background

microRNA (miRNA) constitutes a class of small non-coding RNAs, which are involved in cell proliferation, differentiation, and progression of tumors. miRNAs and their target molecules are utilized for molecular diagnosis of urothelial carcinoma. Nucleus accumbens-associated protein 1 (NACC1), one of several transcription factors, is constitutively expressed in the urothelium, wherein it regulates cell growth, senescence, autophagy, epithelial-mesenchymal transition. We previously reported that NACC1 is the target molecule of miR-331-3p and is associated with cell proliferation in prostate and cervical cancer.

Methods

Functional experiments involving miR-331-3p and its target molecule, NACC1, was analyzed using urothelial carcinoma (UC) cell lines, T24, UMUC6, and KU7. Quantitative reverse transcription polymerase chain reaction, and immunostaining were performed to evaluate the expression of miR-331-3p and NACC1 in UC derived from transurethral resection of bladder tumor (TUB-Bt) specimens.

Results

The MTS assay revealed that cell proliferation was significantly reduced after transient transfection of miR-331-3p precursor and/or NACC1 siRNA in UC cells. Cell senescence via cell cycle arrest at the G1 phase was induced by NACC1 inhibition. Immunohistochemistry with TUR-Bt specimens revealed that greater than 90% of both UC and normal urothelial cells were positive for NACC1 in contrast to no or limited expression in squamous cell carcinoma of the esophagus, cervix, and oral cavity. The NACC1 expression profile is not significantly associated with the pathological parameters including the pT stage.

Conclusions

The present results suggest that NACC1 regulated by miR-331-3p contributes to cell proliferation and is a new potential target molecule for the diagnosis and treatment of UC.

Clinical trial identification

Legal entity responsible for the study

Nara Medical University.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings